CO5280211A1 - Forma de cristal de eplerenona que exhibe mejorada rata de disolucion - Google Patents

Forma de cristal de eplerenona que exhibe mejorada rata de disolucion

Info

Publication number
CO5280211A1
CO5280211A1 CO00094075A CO00094075A CO5280211A1 CO 5280211 A1 CO5280211 A1 CO 5280211A1 CO 00094075 A CO00094075 A CO 00094075A CO 00094075 A CO00094075 A CO 00094075A CO 5280211 A1 CO5280211 A1 CO 5280211A1
Authority
CO
Colombia
Prior art keywords
eplerenone
crystalline
rat
crystal form
exhibiting improved
Prior art date
Application number
CO00094075A
Other languages
English (en)
Spanish (es)
Inventor
P Barton Kathleen
Thomas B Borehardt
V Carlos Marlon
Desai Subhash
Leonard J Ferro
Henry T Gaud
Scott Ganser
Clay R Little
S Mudipalli Partha
Mark A Pietz
Daniel R Pilipauskas
L Sing Yuen-Lung
Glen L Stahl
Joseph J Wieczoreck
Y Chris Yan
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5280211A1 publication Critical patent/CO5280211A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CO00094075A 1999-12-08 2000-12-11 Forma de cristal de eplerenona que exhibe mejorada rata de disolucion CO5280211A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16963999P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16969099P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08

Publications (1)

Publication Number Publication Date
CO5280211A1 true CO5280211A1 (es) 2003-05-30

Family

ID=27558585

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00094075A CO5280211A1 (es) 1999-12-08 2000-12-11 Forma de cristal de eplerenona que exhibe mejorada rata de disolucion

Country Status (17)

Country Link
EP (1) EP1177204A2 (enExample)
JP (1) JP2003516414A (enExample)
KR (1) KR100607923B1 (enExample)
CN (2) CN1152886C (enExample)
AU (1) AU784946B2 (enExample)
BR (1) BR0008057A (enExample)
CA (1) CA2362669A1 (enExample)
CO (1) CO5280211A1 (enExample)
EA (1) EA007934B1 (enExample)
HU (1) HUP0203032A3 (enExample)
IL (3) IL144764A0 (enExample)
MX (1) MXPA01008056A (enExample)
MY (1) MY131878A (enExample)
NO (1) NO20013856L (enExample)
NZ (2) NZ530028A (enExample)
PE (1) PE20010917A1 (enExample)
WO (1) WO2001042272A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487540A2 (en) * 2002-03-20 2004-12-22 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
EP2568986B1 (en) 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции
CN120754115A (zh) * 2025-05-23 2025-10-10 远大医药（中国）有限公司 一种含依普利酮组合物及其药物制剂、制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
NZ336004A (en) * 1996-12-11 2001-04-27 G Process for preparation of 3-keto-7-alpha-alkoxycarbonyl substituted delta-4,5-steroid by reacting 4,5-dihydro-5,7-lactone steroid substrate in the presence of a base
JP2002538172A (ja) * 1999-03-05 2002-11-12 ジー．ディー．サール エルエルシー 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法

Also Published As

Publication number Publication date
HUP0203032A3 (en) 2003-04-28
BR0008057A (pt) 2002-04-23
CN1377365A (zh) 2002-10-30
WO2001042272A9 (en) 2002-12-12
CA2362669A1 (en) 2001-06-14
WO2001042272A2 (en) 2001-06-14
IL144764A (en) 2007-08-19
MXPA01008056A (es) 2003-07-21
HUP0203032A2 (hu) 2002-12-28
NO20013856D0 (no) 2001-08-08
KR100607923B1 (ko) 2006-08-04
EA007934B1 (ru) 2007-02-27
KR20010112261A (ko) 2001-12-20
HK1050536A1 (en) 2003-06-27
PE20010917A1 (es) 2001-09-10
NZ513961A (en) 2004-02-27
NZ530028A (en) 2005-08-26
WO2001042272A3 (en) 2001-11-29
IL144764A0 (en) 2002-06-30
AU784946B2 (en) 2006-08-03
CN1152886C (zh) 2004-06-09
EA200100871A1 (ru) 2002-04-25
CN1557833A (zh) 2004-12-29
JP2003516414A (ja) 2003-05-13
NO20013856L (no) 2001-10-08
EP1177204A2 (en) 2002-02-06
MY131878A (en) 2007-09-28
AU2049201A (en) 2001-06-18
IL176511A (en) 2007-08-19

Similar Documents

Publication Publication Date Title
AU782631C (en) Novel heterocyclic compounds and salts thereof and medicinal use of the same
GB2374302B (en) Power material for electrostatic application to a substrate and electrostatic application of the powder material to a substrate
CA2335179A1 (en) Tablet and process for making the same
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
HUP9901960A3 (en) Pharmaceutical compositions containing crystalline ziprasidone and process for preparation of the crystals
IL145071A0 (en) Fused ring compounds and pharmaceutical compositions containing the same
EP1677730A4 (en) DRUG DISPENSES BASED ON REVERSE PHASE LIQUID CRYSTAL MATERIALS
WO2001041770A3 (en) Nanoparticulate eplerenone compositions
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
HUP0600593A2 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents and pharmaceutical compositions thereof
BR0206164A (pt) Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
HUP0003133A3 (en) Ace-inhibitor nitric salts and use of them for producing pharmaceutical compositions
DE60139462D1 (de) Arzneimittel zur gesteuerten freisetzung von paracetamol
CO5770095A1 (es) Forma cristalina gamma-d del clorhitrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
AR070107A1 (es) R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
GB0204772D0 (en) Pharmaceutical dosage forms
SG111967A1 (en) An injectable pharmaceutical composition containing a non-steriodal anti-inflammatory drug and method for preparing the same
ATE238070T1 (de) Komplex aus carrageenan und einem wasserlöslichen medikament mit einer spezifischen granulometrie und entsprechende pharmazeutische zusammensetzungen mit gesteuerter freisetzung
HUP0104009A3 (en) New crystal modification of torasemide, process for its preparation, its use as a ran material and pharmaceutical compositions containing it
NZ513961A (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
NO20012351D0 (no) Farmasöytisk sammensetning for modifisert frigjöring av insulinsensibiliserende middel
MY125975A (en) Crystalline form vii of cabergoline
HUP9903747A3 (en) New process for the preparation of mometasone furoate
PE20010918A1 (es) Forma cristalina de eplerenona
MX9203615A (es) Composicion farmaceutica en forma de polvo para administracion nasal.

Legal Events

Date Code Title Description
FC Application refused